Regenerative Stem cell therapy for Myocardial Infarction: Telmisartan/Micardis, an angiotensin II receptor antagonist, improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 13/April/2015, 09.10 am

Regenerative therapy for Diabetes mellitus: Cardiotrophin-1 (CT-1) increases human pancreatic beta cell replication via down regulation of its target gene DYRK1A, 13/April/2015, 12.28 am
April 12, 2015
Small molecule-based Lifespan extension therapy: Exendin-4/Exenatide, a Glucagon-Like Protein-1 (GLP-1) Receptor Agonist, may prolong mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 13/April/2014, 11.14 am
April 13, 2015
Show all

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports a small molecule-based Regenerative Stem cell therapy for Myocardial Infarction:  Telmisartan/Micardis, an angiotensin II receptor antagonist, improves myocardial function after myocardial infarction via  up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10). 

Significance: 

Telmisartan/Micardis is used in the treatment of HypertensionDiabetic nephropathyHeart failure and Left ventricular systolic dysfunctionThis study suggests, for the first time, that Telmisartan/Micardis, by increasing the expression of its target gene, it may increase the expression of PNUTS/PPP1R10. Thereby, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardimyocyte survival/regeneration. Therefore, by consuming Telmisartan/Micardis, one may protect himself/herself from ageing-associated decline in cardiac function. Together, pharmacological formulations encompassing “Telmisartan/Micardis or its analogues” may be used to improve cardiac function after myocardial infarction

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Regenerative Stem cell therapy for Myocardial Infarction: Telmisartan/Micardis, an angiotensin II receptor antagonist, improves myocardial function after myocardial infarction via  up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 13/April/2015,  09.10 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How  Telmisartan/Micardis  increases the expression of PNUTS/PPP1R10

Comments are closed.